Office Hysteroscopy Moves Deeper Into the Treatment Pathway
Office-based operative hysteroscopy is no longer a fringe alternative to the operating room. Smaller operative systems have made it possible to remove selected intrauterine lesions without cervical dilation, sedation, or general anesthesia, and the current study at Shaare Zedek Medical Center is designed to define which patients are most likely to do well with that approach.
The study focuses on office operative hysteroscopy using a mini-resectoscope for benign intrauterine pathology, specifically endometrial polyps and retained products of conception up to 2.5 cm. The clinical question is straightforward but important: which demographic, gynecologic, clinical, and hysteroscopic variables predict procedural success, and which ones forecast severe pain or an incomplete procedure?
This is a prospective observational single-arm study, not a randomized comparison. Fifty adult women are expected to be enrolled, all in an outpatient gynecology setting, with procedures performed without anesthesia by experienced hysteroscopists using a standardized office-based approach.
Why Patient Selection Now Matters More Than Device Availability
The appeal of office hysteroscopy rests on efficiency, avoidance of anesthesia exposure, and quicker treatment of common intrauterine conditions. Yet the same features that make the procedure attractive also make selection critical. A narrow cervical canal, distorted uterine orientation, lesion morphology, or a difficult access route can turn a short outpatient procedure into a painful or incomplete one.
The mini-resectoscope is designed to address some of those barriers. Its reduced outer diameter may lessen the need for cervical dilation and improve feasibility in patients who would otherwise need an operating-room setting. Even so, the device does not erase biologic and anatomic variability. Pain perception remains one of the main limitations of office hysteroscopy, and the study is built around that reality.
A key endpoint is procedural success, defined as complete removal of the intrauterine pathology. Another is severe pain, defined by a Visual Analog Scale score greater than 7. A third question asks whether procedures lasting more than 3 minutes are linked to higher intraoperative pain scores. The protocol also compares success rates between procedures done for endometrial polyps and those done for retained products of conception.
Severe pain is the outcome that can abruptly end an office procedure.
Anatomy, Pain, and the Limits of an Outpatient Approach
The study’s variable set reflects the known mechanical and sensory obstacles of hysteroscopic surgery. Investigators will record parity, menopausal status, prior cervical procedures, cesarean delivery history, prior hysteroscopic interventions, uterine orientation, cervical stenosis, lesion size and location, lesion morphology, lesion vascularity, and operative duration. These are not abstract descriptors. Each can affect how easily the hysteroscope enters the cavity, how much manipulation is needed, and how long the patient is exposed to distension and instrument contact.
The pathophysiology of pain during office hysteroscopy is familiar to gynecologic surgeons. Pain can arise from cervical traversal, uterine distension, traction, fluid pressure, and manipulation at the endometrial surface. Lesions near the fundus or in anatomically difficult positions may require longer operative time and more instrument movement, increasing nociceptive stimulation. In a uterus with challenging orientation or fibrotic access, even a small lesion can become technically demanding.
Pain will be assessed during the procedure and again 5 minutes afterward using the VAS, a validated tool for procedural discomfort. That immediate second measurement is useful because it captures early recovery after the hysteroscope is withdrawn and the cavity is no longer being manipulated. It also offers a short window into whether the pain burden fades quickly or lingers after a difficult intervention.
Endometrial Polyps and Retained Products Bring Different Procedural Risks
The enrolled population includes women with suspected or confirmed endometrial polyps and retained products of conception. Both conditions are common reasons for operative hysteroscopy, but they are not identical from a technical standpoint. Polyps are often discrete and focal, while retained products may vary in adherence, vascularity, and degree of intrauterine distortion. Those differences may affect how easily a lesion can be removed under office conditions and how much bleeding, manipulation, or time the procedure requires.
The protocol caps lesion size at 2.5 cm and allows up to two lesions in the cavity. That restriction should enrich the cohort for patients who are realistically considered for outpatient treatment. It also means the study is aimed at a clinically relevant middle ground: cases that are not trivial, but still small enough to be candidates for a see-and-treat strategy.
Exclusion criteria further narrow the population. Patients with known cervical stenosis, prior failure of office operative hysteroscopy without anesthesia, known endometrial malignancy, or a need for operating-room hysteroscopy under general anesthesia are not eligible. Those exclusions are sensible if the goal is to map predictors within a group actually considered suitable for office treatment.
What the Results Could Change at the Bedside
If this cohort identifies a reliable pattern of success and tolerability, the practical payoff could be substantial. Better patient selection may reduce unnecessary exposure to general anesthesia, streamline counseling, and help outpatient clinics reserve office operative hysteroscopy for those most likely to complete it comfortably. In a system already pushing to shorten wait times and preserve operating-room resources, that kind of triage has immediate operational value.
The study design also has a built-in caution. Because it is observational and single-arm, it can identify associations but not prove causality. The sample size is modest at 50 patients, and the work will be done in one center with experienced hysteroscopists, which may limit how widely the findings can be applied. Still, the prospective collection of pain scores, technical variables, and procedural outcomes should generate useful data in a field where office-based decision-making often depends on experience rather than formal prediction rules.
The study begins with an estimated start date of October 2026, with primary completion projected for November 2027 and final completion in December 2027. Those dates place the readout well into the future, but the clinical question is already pressing now: which women can safely and comfortably complete hysteroscopic removal of small benign intrauterine lesions without anesthesia, and which women are more likely to need a different setting?
A Narrower, More Actionable Operating Room Alternative
The investigation is built around a simple proposition: the office can be the right place for many hysteroscopic procedures, but not all of them. Lesion size, cervical access, uterine anatomy, and procedure duration may separate a smooth outpatient case from a painful failure. By measuring those variables prospectively, the study could help move office hysteroscopy from an experience-driven practice to a more structured selection process.
If the predictors prove consistent, the result will not be a new device or a new drug. It will be a better way to decide who should be treated in the office, who should be warned about pain, and who should be sent directly to the operating room before the procedure begins.